Menu
Your Cart

Melox 7.5Mg

Melox 7.5Mg - (000513) - www.mycare.lk
Melox 7.5Mg - (000513) - www.mycare.lk
Melox 7.5Mg - (000513) - www.mycare.lk
Melox 7.5Mg - (000513) - www.mycare.lk
Melox 7.5Mg - (000513) - www.mycare.lk
Melox 7.5Mg - (000513) - www.mycare.lk
Melox 7.5Mg - (000513) - www.mycare.lk
Melox 7.5Mg - (000513) - www.mycare.lk
Melox 7.5Mg
Rs.12.25
Price per unit
  • Stock: 787
  • Model: Melox 7.5Mg
  • SKU: 000513
  • Pack size: 100
  • Generic name: Meloxicam
Add to Cart

Composition Melox 7.5 Tablets Each uncoated tablet contains Meloxicam BP 7.5mg. Melox 15 Tablets Each uncoated tablet contains Meloxicam BP 15mg. 

Prescription: Cyclooxygenase 2 (COX-2) inhibition is the relevant target for the anti-inflammatory effects of NSAIDs, whereas the inhibition of constitutive COX-1 is responsible for the gastric and renal side effects as well as antithrombotic activity of these agents. Meloxicam is a new NSAID belonging to the oxicam family, which has shown preferential COX-2 inhibition. The anti-inflammatory, analgesic, and antipyretic effects of meloxicam are due to inhibition of prostaglandin which are known mediators of inflammation. 

Indications: Meloxicam is indicated in the following: short term symptomatic treatment of acute exacerbations of osteoarthritis. Long term symptomatic treatment of rheumatoid arthritis. 

Contraindications: Hypersensitivity to meloxicam or any other constituents. Patients who have developed signs of asthma, nasal polyps, angioneurotic oedema or urticaria following the administration of aspirin or other NSAlDs. Active peptic ulcer during the last six months. History of recurrent peptic ulcer  

disease. Severe hepatic failure non-dialyzed severe renal failure Gastrointestinal cerebrovascular bleeding or other bleeding disorders. 

Warnings and Precautions: As with all NSAlDs, any history of esophagitis, gastritis and/ or peptic ulcer must be sought in order to ensure their total cure before starting treatment with meloxicam. Long term administration of meloxicam, like other NSAlDs is associated with an increase in gastrointestinal side effects. In case of onset of peptic ulcer or gastrointestinal bleeding, treatment with meloxicam should be stopped. Increased liver function parameters as well as increase in serum creatinine and blood urea nitrogen as well as other laboratory disturbances have been reported. These involve transitory and slight abnormalities. If these abnormalities prove significant or persistent, meloxicam Should be stopped, and investigations prescribed. Rarely skin reactions, interstitial nephritis, glomerulonephritis may be associated with NSAID. Patients with cardiac insufficiency or hypertension should be treated with caution. NSAlDs should be administered with caution in patients with decreased renal blood flow and blood volume in which renal prostaglandins are involved in the renal perfusion as administration in such situations may lead to decompensation of latent renal failure. Renal function returns to its initial state when the treatment is withdrawn. 

Side Effects: The adverse effects reported with meloxicam are as listed below. These adverse effects occur occasionally and are mild to moderate in severity and are transient in nature. Adverse effects related to digestive system: dyspepsia, nausea, vomiting, abdominal pain, constipation, flatulence, diarrhea. More rarely, ulcer or occult gastrointestinal bleeding may occur, taking sometimes the form of chronic gastrointestinal blood loss. Hematological adverse effects: All NSAlDs are reported to cause some or other form of hematological adverse effects which include disturbances of blood count, differential white blood cell count, anemia, leukopenia, thrombocytopenia. But only certain adverse effects listed above have been attributed to treatment with meloxicam. Concomitant administration of a potentially myelotoxic drug methotrexate, appears to be a predisposing factor to the onset of cytopenia. Also, a case of agranulocytosis has been described in a patient treated with meloxicam and taking methotrexate. Cutaneo-mucosal adverse effects: Stomatitis, esophagitis, pruritus, skin rash, urticaria, photosensitizations have been reported. Adverse effects related to respiratory system: Onset of an asthma attack has been reported in certain individuals allergic to aspirin or to other NSAlDs Adverse effects related to central nervous system: Light-headedness, headache, vertigo, tinnitus, drowsiness Adverse effects related to cardiovascular system: Pedal oedema, palpitations, flushes. Genitourinary system: Disturbances of laboratory tests investigating renal function (e.g., raised serum Creatinine or urea). 

Overdosage: Appropriate measures are required in case of overdose since there is no known antidote. Evidence was found in a clinical trial of acceleration of the elimination of meloxicam by cholestyramine Severe gastrointestinal lesions may be treated antacids and H2 receptor antagonist. 


Manufactured by: CIPLA LTD 

Write a review

Note: HTML is not translated!
Bad Good